The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. (Q38353745)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

1

Seiji Mabuchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Ryoko Takahashi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

Tomoyuki Sasano

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

10 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

173-179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Rethinking ovarian cancer: recommendations for improving outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

PI3K and cancer: lessons, challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

mTOR signaling in growth control and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Targeting mTOR Signaling Pathway in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Activation of mTORC2 by Association with the Ribosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

PTEN expression in clear cell adenocarcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Targeting the phosphoinositide 3-kinase pathway in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

PI3Kδ inhibition hits a sensitive spot in B cell malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Metformin: an old drug with new potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Genomic complexity and AKT dependence in serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.02.003

10.1016/J.YGYNO.2015.02.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25677064 AND SRC:MED&resulttype=core&format=json

29 February 2020

1 reference